Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

Overview

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2013

Interventions

  • Device: ADVOS (Hepa Wash)
    • Intervention frequency: 1-10 treatments (decision of the investigator) Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
  • Procedure: Standard Medical Therapy
    • Standard of care treatment

Arms, Groups and Cohorts

  • Experimental: ADVOS (Hepa Wash)
    • Treatment with the liver support system “Hepa Wash”

Clinical Trial Outcome Measures

Primary Measures

  • 30-day mortality rate
    • Time Frame: 30 days
    • Mortality 30 days after the first intervention

Secondary Measures

  • Multiorgan system failure according to Sequential Organ Failure Assessment (SOFA) Score
    • Time Frame: 72 hours
    • The Sequential Organ Failure Assessment (SOFA) Score analyses the severity of illness according to 6 organ systems (CNS, Liver, Kidney, Hemodynamic, Coagulation, Lung). Each system is given 0 to 4 points for a total of 24 points. A value >2 in each of the systems indicates organ failure. An overall value > 14 indicates 90% probability of in-hospital mortality.
  • Safety (adverse events and surrogate parameters)
    • Time Frame: 30 days
    • Adverse Events during the intervention will be assessed. Additionally, liver parameters (e.g. Bilirubin), Kidney Parameters (e.g. Creatinin, Urea) and blood gas analysis will be performed.
  • Number of days on ventilation
    • Time Frame: 30 days
    • Number of days with need of mechanical ventilation after first intervention
  • Number of days without extracorporeal treatment
    • Time Frame: 30 days
    • Number of days without the need of extracorporeal renal and/or liver replacement therapy after the first intervention
  • 180d-mortality rate
    • Time Frame: 180 days
    • Mortality 180 days after the first intervention
  • 1y-mortality rate
    • Time Frame: 1 year
    • Mortality 1 year after the first intervention

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with documented clinical or histological evidence of cirrhosis AND 2. Acute decompensation in previously stable cirrhotic liver disease AND 3. Bilirubin ≥ 2 mg/dl AND 4. SOFA ≥ 9 calculated after 12 hours of optimal medical therapy AND 5. Patient is in the intensive care unit AND 6. Informed consent of the patient or the legal representative AND 7. Patients are 18y or older AND 8. Enrollment of patients within 96 hours of fulfilling inclusion criteria (1-5) Exclusion Criteria:

1. Untreatable extrahepatic cholestasis 2. Patient has a survival prognosis of less than 6 weeks because of a chronic disease (e.g. metastasizing cancer) and before the acute event which lead to the ICU admission. 3. PaO2/FIO2 ≤ 100 mmHg (respiratory SOFA-score of 4) 4. Patients who receive a vasopressor support of Dopamine >15 µg/kg/min or epinephrine >0.1 µg/kg/min or norepinephrine >0.1 µg/kg/min (cardiovascular SOFA-score of 4) 5. Patients with creatinine ≥5 mg/dl or urine output <200 ml/day (renal SOFA-score of 4) 6. Patients on kidney dialysis 7. Patient with MELD-score of 40 8. Mean arterial pressure ≤ 50 mmHg despite conventional medical treatment 9. Patient testament excludes the use of life-prolonging measures 10. Post-operative patients whose liver failure is related to liver surgery 11. Uncontrolled seizures 12. Active or uncontrolled bleeding 13. Weight ≥ 120 kg 14. Pregnancy 15. Patient diagnosed with Creutzfeldt-Jakob disease 16. Participation in another clinical study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hepa Wash GmbH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wolfgang Huber, PD Dr., Principal Investigator, II Medizinische Klinik, Klinikum rechts der Isar, Munich

Citations Reporting on Results

Huber W, Henschel B, Schmid R, Al-Chalabi A. First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis. BMC Gastroenterol. 2017 Feb 16;17(1):32. doi: 10.1186/s12876-017-0569-x.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.